| Metyas, Samy |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout |
|
|
| Recruiting | 4 | 240 | US | Pegloticase, Methotrexate | Amgen | Gout | 09/25 | 05/26 | | |
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 4 | 350 | Europe, Japan, US, RoW | Belimumab (GSK1550188), BEL (BENLYSTA) | GlaxoSmithKline | Systemic Lupus Erythematosus | 04/27 | 05/29 | | |
| Recruiting | 4 | 1300 | US | Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab | Eli Lilly and Company, Incyte Corporation | Rheumatoid Arthritis | 12/24 | 02/26 | | |
| Recruiting | 4 | 715 | Europe, US, RoW | Secukinumab s.c. injection | Novartis Pharmaceuticals | Autoimmunity, Inflammation | 12/27 | 02/28 | | |
| Completed | 3 | 275 | US | Digital ACT, Digital Symptom Tracker | Swing Therapeutics, Inc. | Fibromyalgia | 05/23 | 05/23 | | |
| Terminated | 3 | 275 | Europe, Canada, Japan, US, RoW | secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Lupus Nephritis | 09/23 | 09/23 | | |
| Active, not recruiting | 3 | 243 | US | Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation | SetPoint Medical Corporation | Rheumatoid Arthritis | 05/24 | 10/27 | | |
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) |
|
|
| Active, not recruiting | 3 | 292 | Europe, Japan, US, RoW | TILD, matching placebo injections | Sun Pharmaceutical Industries Limited | Active Psoriatic Arthritis | 09/24 | 12/24 | | |
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) |
|
|
| Recruiting | 3 | 472 | Europe, Canada, US, RoW | TILD, matching placebo injections | Sun Pharmaceutical Industries Limited | Active Psoriatic Arthritis | 05/25 | 02/26 | | |
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriatic Arthritis, Obesity | 04/26 | 08/26 | | |
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 61 | Europe, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 10/24 | 12/24 | | |
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 491 | Europe, Canada, Japan, US, RoW | Peresolimab, Placebo | Eli Lilly and Company | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 11/23 | 01/25 | | |
| Recruiting | N/A | 28 | Europe, US | Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment | Galvani Bioelectronics, NAMSA, Q2 Solutions | Rheumatoid Arthritis | 07/27 | 04/32 | | |
